Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol  Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,

Slides:



Advertisements
Similar presentations
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Advertisements

Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis  George Griesinger, M.D.,
Pulsatile gonadotropin-releasing hormone therapy in persistent amenorrheic weight- recovered anorexia nervosa patients  Natacha Germain, M.D., Ph.D., Anaïs.
Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration  Jean-noêl Hugues,
Follicular and endocrine response to anastrozole versus clomiphene citrate administered in follicular phase to normoovulatory women: a randomized comparison 
Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis 
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Leptin levels and luteinizing hormone pulsatility in normal cycling women and their relationship to daily changes in metabolic rate  Rebecca M. Fenichel,
The normal variabilities of the menstrual cycle
Fernando Zegers-Hochschild, M.D.  Fertility and Sterility 
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
Michael M. Alper, M.D.  Fertility and Sterility 
Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis  Ioannis P. Kosmas, M.D.,
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist.
The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.
Isabel Pereira, M. D. , Kyra von Horn, M. D. , Marion Depenbusch, M. D
Conservative management of cervical ectopic pregnancy
Impact of fatness, insulin, and gynecological age on luteinizing hormone secretory dynamics in adolescent females  Josephine Z. Kasa-Vubu, M.D., Vandana.
Failure of the GnRH antagonist ganirelix to block the positive feedback effect of exogenous estrogen in normal women  Ioannis E. Messinis, M.D., Ph.D.,
Potential diagnostic utility of intermittent administration of short-acting gonadotropin- releasing hormone agonist in gonadotropin deficiency  Carrie.
Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.
Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles  Tsung-Hsien.
Oocyte cryopreservation
Leptin levels and luteinizing hormone pulsatility in normal cycling women and their relationship to daily changes in metabolic rate  Rebecca M. Fenichel,
Prevalence of premature urinary luteinizing hormone surges in women with regular menstrual cycles and its effect on implantation of frozen-thawed embryos 
Robert F. Casper, M.D.  Fertility and Sterility 
Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration 
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.
Serum luteinizing hormone levels are markedly increased and significantly correlated with Δ4-androstenedione levels in lean women with polycystic ovary.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility  Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Laparoscopic management of early primary omental pregnancy
Introduction Fertility and Sterility
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro.
Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.
Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting  Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.
Fertility and Sterility
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
Sperm to zona pellucida binding depends on the use of a gonadotropin-releasing hormone agonist or a gonadotropin-releasing hormone antagonist  Annika.
Website quality assessment: Mistaking apples for oranges
Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men  Subodhsingh Chauhan, M.D.,
The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is.
Fertility and Sterility: an evaluation
Physical health at 5.5 years of age of term-born singletons after intracytoplasmic sperm injection: results of a prospective, controlled, single-blinded.
Paolo Moghetti, M.D.  Fertility and Sterility 
Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins:
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Administration of gonadotropin-releasing hormone antagonist from day 1 of stimulation in in vitro fertilization  Efstratios M Kolibianakis, M.D., Kostas.
Impact of luteinizing hormone administration on gonadotropin-releasing hormone antagonist cycles: an age-adjusted analysis  Ernesto Bosch, M.D., Elena.
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.
Ariel Fuentes, M. D. , Alex Muñoz, B. S. , Kurt Barnhart, M. D
Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists 
Aline Ketefian, M. D. , Jianfang Hu, Ph. D. , Alfred A. Bartolucci, Ph
Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study  Ahmed Badawy, M.D., Aboubakr.
The gonadotropin-releasing hormone (GnRH)-1 gene, the GnRH receptor gene, and their promoters in patients with idiopathic hypogonadotropic hypogonadism.
Nerve fibers and menstrual cycle in peritoneal endometriosis
In vitro sildenafil citrate use as a sperm motility stimulant
Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian.
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation 
Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:
Oocyte retrieval timing based on spontaneous luteinizing hormone surge during natural cycle in vitro fertilization treatment  Daniel Bodri, M.D., M.Sc.,
Presentation transcript:

Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol  Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau, M.D., Dominique Finas, M.D., Klaus Diedrich, M.D., Ph.D., Ricardo Felberbaum, M.D., Ph.D.  Fertility and Sterility  Volume 85, Issue 3, Pages 791-793 (March 2006) DOI: 10.1016/j.fertnstert.2005.08.048 Copyright © 2006 American Society for Reproductive Medicine Terms and Conditions

FIGURE 1 A 32-hour LH secretory profile (lower panel) with corresponding serum concentration series (upper panel). Only significant secretory peaks are depicted. Arrows indicate the time points of 0.25-mg cetrorelix administration. Griesinger. Assessment of LH in the GnRH antagonist protocol. Fertil Steril 2006. Fertility and Sterility 2006 85, 791-793DOI: (10.1016/j.fertnstert.2005.08.048) Copyright © 2006 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.